ArticleMicrobial biotechnology2019
Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: the case of VSL#3.
Article in Microbial biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Trial
- Spatio-temporal dynamics of the human small intestinal microbiome and its response to a synbiotic.Gut microbesTrial
- Influence of Probiotic Administration on Tracheoesophageal Voice Prosthesis's Function and Microbial Colonisation: A Pilot Study.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Article
- Protective Effect of a Heat-Stabilized Bacteria Probiotic Preparation (VSL#3-HS) in a Mouse Model of Ulcerative Colitis Induced by Dextran Sulfate Sodium.Molecular nutrition & food research · 2026Article
- Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers.Biology · 2026Review
- High stability of the genome ofMicrobiology spectrum · 2026Article
- Milk and Its Derivatives as Sources of Components and Microorganisms with Health-Promoting Properties: Probiotics and Bioactive Peptides.Foods (Basel, Switzerland) · 2024Review
- Insights from metagenome-assembled genomes on the genetic stability and safety of over-the-counter probiotic products.Current genetics · 2023Article
- Review
- Perspectives and advances in probiotics and the gut microbiome in companion animals.Journal of animal science and technology · 2022Review
- Microbiological Quality and Resistance to an Artificial Gut Environment of Two Probiotic Formulations.Foods (Basel, Switzerland) · 2021Article
- The Probiotic VSL#3Pharmaceuticals (Basel, Switzerland) · 2021Article
- Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Review
- Spotlight on the Compositional Quality of Probiotic Formulations Marketed Worldwide.Frontiers in microbiology · 2021Review
- Bulk and Surface Wettability Characteristics of Probiotic Powders in Their Compressed Disc and Packed-Bed Column Forms.ACS omega · 2020Article
- The Neglected Microbial Components of Commercial Probiotic Formulations.Microorganisms · 2020Article
- Review
- Global analysis of clinical trials with probiotics.Heliyon · 2020Review
- Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.World journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing commercial interest in multi-strain formulations marketed as probiotics has not been accompanied by an equal increase in the evaluation of quality levels of these biotechnological products. The multi-strain product VSL#3 was used as a model to setup a microbiological characterization that could be extended to other formulations with high complexity. Shotgun metagenomics by deep Illumina sequencing was applied to DNA isolated from the commercial VSL#3 product to confirm strains identity safety and composition. Single-cell analysis was used to evaluate the cell viability, and β-galactosidase and urease activity have been used as marker to monitor the reproducibility of the production process. Similarly, these lots were characterized in detail by a metaproteomics approach for which a robust protein extraction protocol was combined with advanced mass spectrometry. The results identified over 1600 protein groups belonging to all strains present in the VSL#3 formulation. Of interest, only 3.2 % proteins showed significant differences mainly related to small variations in strain abundance. The protocols developed in this study addressed several quality criteria that are relevant for marketed multi-strain products and these represent the first efforts to define the quality of complex probiotic formulations such as VSL#3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.